New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events

References

• GoldhaberSZPulmonary embolism thrombolysis: a clarion call for international collaborationJ Am Coll Cardiol19921922462471732348
   PubMed Web of Science ®Google Scholar
• Gómez-OutesASuárez-GeaMLCalvo-RojasGDiscovery of anticoagulant drugs: a historical perspectiveCurr Drug Discov Technol2012928310421838662
   PubMedGoogle Scholar
• HolyEWBeerJHUpdate on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillationCardiovasc Med201316103114
   Google Scholar
• HeidbuchelHVerhammePAlingsMEuropean Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillationEuropace201315562565123625942
   PubMed Web of Science ®Google Scholar
• CampbellHARobertsWLSmithWKLinkKPStudies of the hemorrhagic sweet clover disease. I. The preparation of hemorrhagic concentratesJ Biol Chem19401364755
   Google Scholar
• FerlundPStenfloJRoepstorffPThomsenJVitamin K and the biosynthesis of prothrombin. V. Gamma-carboxyglutamic acids, the vitamin K-dependent structures in prothrombinJ Biol Chem1975250156125613350323
   PubMed Web of Science ®Google Scholar
• HirshJDalenJEAndersonDROral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic rangeChest1998114445S469S9822057
   PubMed Web of Science ®Google Scholar
• FascoMJHildebrandtEFSuttieJWEvidence that warfarin anticoagulant action involves two distinct reductase activitiesJ Biol Chem19822571911210112126811577
   PubMed Web of Science ®Google Scholar
• ChoonaraIAMaliaRGHaynesBPThe relationship between inhibition of vitamin K1 2,3-epoxide reductase and reduction of clotting factor activity with warfarinBr J Clin Pharmacol1988251173370190
   PubMed Web of Science ®Google Scholar
• IckxBESteibAPerioperative management of patients receiving vitamin K antagonistsCan J Anaesth2006536 SupplS113S12216766784
   PubMed Web of Science ®Google Scholar
• KlauserWDütschMPartial management of new oral anticoagulants after total hip or total knee arthroplastyMusculoskelet Surg201397318919724249360
   PubMedGoogle Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• da SilvaRMNovel oral anticoagulants in non-valvular atrial fibrillationCardiovasc Hematol Agents Med Chem20141213825470147
   PubMedGoogle Scholar
• GayleJAKayeADKayeAMShahRAnticoagulants: newer ones, mechanisms, and perioperative updatesAnesthesiol Clin201028466767921074744
   PubMedGoogle Scholar
• BlechSEbnerTLudwig-SchwellingerEStangierJRothWThe metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humansDrug Metab Dispos200836238639918006647
   PubMed Web of Science ®Google Scholar
• StangierJRathgenKStähleHGansserDRothWThe pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjectsBr J Clin Pharmacol200764329230317506785
   PubMed Web of Science ®Google Scholar
• Gómez-OutesATerleira-FernándezAICalvo-RojasGSuárez-GeaMLVargas-CastrillónEDabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroupsThrombosis2013201364072324455237
   PubMedGoogle Scholar
• HohnloserSHOldgrenJYangSMyocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trialCirculation2012125566967622215856
   PubMed Web of Science ®Google Scholar
• ArtangRRomeENielsenJDVidailletHJMeta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitorsAm J Cardiol2013112121973197924075284
   PubMed Web of Science ®Google Scholar
• GrahamDJReichmanMEWerneckeMCardiovascular, bleeding, and mortality risk in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillationCirculation2015131215716425359164
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKRE-COVER Study GroupDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKGoldhaberSZRE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysisCirculation2014129776477224344086
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF InvestigatorsRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• LittleJWNew oral anticoagulants: will they replace warfarin?Oral Surg Oral Med Oral Pathol Oral Radiol2012113557058022668617
   PubMed Web of Science ®Google Scholar
• HoffmanRBrennerBThe promise of novel direct oral anticoagulantsBest Pract Res Clin Haematol201225335136022959551
   PubMed Web of Science ®Google Scholar
• GulsethMPMichaudJNutescuEARivaroxaban: an oral direct inhibitor of factor XaAm J Health Syst Pharm200865161520152918693206
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-3939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjectsEur J Clin Pharmacol2005611287388016328318
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMVoithBZuehlsdorfMWensingGSafety, pharmacodynamics, and pharmacokinetics of single doses of BAY-59-7939, an oral, direct factor Xa inhibitorClin Pharmacol Ther200578441242116198660
   PubMed Web of Science ®Google Scholar
• TurpieAGOral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseasesArterioscler Thromb Vasc Biol20072761238124717379841
   PubMed Web of Science ®Google Scholar
• WeinzCRadkeMSshmreerRIn vitro metabolisem of BAY 5979-39 and oral, direct factor Xa inhibitorDrug Metab Rev200436Supp 198
   Google Scholar
• ErikssonBIBorrisLCDahlOEODIXa-HIP Study InvestigatorsA once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacementCirculation2006114222374238117116766
   PubMed Web of Science ®Google Scholar
• TurpieAGFisherWDBauerKAOdiXa-Knee Study GroupBAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJ Thromb Haemost20053112479248616241946
   PubMed Web of Science ®Google Scholar
• FrostCSongYBarrettYCA randomized direct comprasion of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxabanClin Pharmacol2014617918725419161
   PubMedGoogle Scholar
• Bayer PharmaAGXarelto (Rivaroxaban) Xarelto®: Summary of Product Characteristics–EU2013 Available from: http://www.xarelto.com/en/information-on-xarelto/summary-of-product-characteristics/Accessed May 1, 2014
   Google Scholar
• MegaJLBraunwaldEWiviottSDATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndromeN Engl J Med2012366191922077192
   PubMed Web of Science ®Google Scholar
• HalabiAKubitzaDZuehlsdorfMEffect of hepatic impairment on the pharmacokinetics and tolerability of rivaroxaban, and oral, direct factor Xa inhibitorJ Thromb Haemost20075Suppl 2P-M-635
   Google Scholar
• EINSTEIN InvestigatorsOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• HirschlMKundiMNew oral anticoagulants in the treatment of acute venous thromboembolism – a systematic review with indirect comparisonsVasa2014435535564
   Web of Science ®Google Scholar
• EINSTEIN-PE InvestigatorsOral rivaroxaba for the treatment symptomatic pulmonary embolismN Engl J Med2012366141287189722449293
   PubMed Web of Science ®Google Scholar
• GallegoPRoldánVLipGYNovel oral anticoagulants in cardiovascular diseaseJ Cardiovasc Pharmacol Ther2014191344424038020
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• ShantsilaELipGYApixaban, an oral, direct inhibitor of activated factor XaCurr Opin Investig Drugs20089910201033
   PubMedGoogle Scholar
• FurugohriTIsobeKHondaYDU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJ Thromb Haemost2008691542154918624979
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo Europe GmbHFirst market approval in Japan for LIXIANA (Edoxaban) [press release]TokyoDaiichi Sankyo Europe GmbH2011422 Available at: http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/005784.htmlAccessed December 1, 2013
   Google Scholar
• O’RiordanM912015FDA Approves Edoxaban for Stroke Prevention in AF and DVT/PE PreventionMedscape Available from: http://www.medscape.com/viewarticle/837837Accessed January 10, 2015
   Google Scholar
• YinOQTetsuyaKMillerREdoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular trial fibrillationEur J Clin Pharmacol201470111339135125168620
   PubMed Web of Science ®Google Scholar
• EikelboomJWWeitzJINew anticoagulantsCirculation2010121131523153220368532
   PubMed Web of Science ®Google Scholar
• FujiTFujitaSTachibanaSKawaiYRandomized, double-blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthoplastyBlood11234 abstract
   PubMed Web of Science ®Google Scholar
• WeitzJIConnollySJPatelIRandomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThromb Haemost201010463364120694273
   PubMed Web of Science ®Google Scholar
• Hokusai-VTE InvestigatorsBüllerHRDécoususHGrossoMAEdoxapan versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658
   PubMed Web of Science ®Google Scholar
• FujiTWangCJFujitaSEdoxaban versus enoxaparin for thrombophylaxis after total knee arthoplasty: the STARS E-3 trialPathophysiol Haemost Thromb201037A20 (OC297)
   Google Scholar
• FujiTFujitaSKawaiYA randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgeryThromb J2015131625653574
   PubMedGoogle Scholar
• RognoniCMarchettiMQuagliniSLiberatoNLEdoxaban versus warfarin for stroke prevention in non-valvular trial fibrillation: a cost-effectiveness analysisJ Thromb Thrombolysis201539214915424973057
   PubMed Web of Science ®Google Scholar
• CohenATSpiroTEBüllerHRRivoroxaban for thrombophylaxis in acutely ill medical patientsN Engl J Med2013368651352323388003
   PubMed Web of Science ®Google Scholar
• CowellRPDirect oral anticoagulants: integration into clinical practicePostgrad Med J201490106752953925012514
   PubMed Web of Science ®Google Scholar
• YatesJChoudhryMKeysGA case report describing a suspected riraroxaban hypersensibility reaction in a surgical patientJ Clin Pharm Ther201338215916123167549
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyPradaxa® – Summary of Product Characteristics2014 Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdfAccessed March 13, 2012
   Google Scholar
• European Medicines AgencyEliquis® – Summary of Product Characteristics2014 Available from: Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed June 2, 2013
   Google Scholar
• SAVAYSA™ (edoxaban) tablets [prescribing information]Parsippany, NJDaiichi Sankyo, Inc.2015 Available from: http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=trueAccessed February 9, 2015
   Google Scholar
• TadrosRShakibSWarfarin-indications, risks and drug interactionsAust Fam Physician201039747647920628660
   PubMedGoogle Scholar
• AbadiSEinarsonAKorenGUse of warfarin during pregnancyCan Fam Physician2002484469569712046363
   PubMedGoogle Scholar
• GarwoodCLCorbettTLUse of anticoagulation in elderly patients with atrial fibrillation who are at risk for fallsAnn Pharmacother200842452353218334606
   PubMed Web of Science ®Google Scholar
• BauerKAPros and cons of new oral anticoagulantsHematology Am Soc Hematol Educ Program2013201346447024319220
   PubMed Web of Science ®Google Scholar
• GnothMJBuetehornUMuensterUSchwarzTSandmannSIn vitro and in vivo P-glycoprotein transport characteristics of rivaroxabanJ Pharmacol Exp Ther2011338137238021515813
   PubMed Web of Science ®Google Scholar
• CrowtherMAWarkentinTEBleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agentsBlood2008111104871487918309033
   PubMed Web of Science ®Google Scholar
• WangLZhangDRaghavanNIn vitro assessment of metabolic drug–drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studiesDrug Metab Dispos201038344845819940026
   PubMed Web of Science ®Google Scholar
• O’ConnellJEStassenLFNew oral anticoagulants and their implications for dental patientsJ Ir Dent Assoc201460313714325080640
   PubMedGoogle Scholar
• KubitzaDBeckaMZuehlsdorfMMueckWBody weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of riraroxaban (BAY 59-7939) in healthy subjectsJ Clin Pharmacol200747221822617244773
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMRothAMueckWThe influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct Factor Xa inhibitorJ Clin Pharmacol201353324925523381840
   PubMed Web of Science ®Google Scholar
• MueckWSchwersSStampfussJRivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoringThromb J20131111023809871
   PubMedGoogle Scholar
• EikelboomJWConnollySJBrueckmannMRE-ALGN InvestigatorsDabigatran versus warfarin in patients with mechanical heart valvesN Engl J Med2013369131206121423991661
   PubMed Web of Science ®Google Scholar
• DouxfilsJTamigniauAChatelainBGoffinetCDognéJMMullierFMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assaysThromb J2014122425750588
   PubMedGoogle Scholar
• BrightonTNew oral anticoagulant drugs – mechanisms of actionAust Prescr2010333841
   Web of Science ®Google Scholar
• WangYBajorekBNew oral anticoagulants in practice: pharmacological practical considerationsAm J Cardiovasc Drugs201414317518924452600
   PubMed Web of Science ®Google Scholar
• KepplingerJBarlinnKGehrischSAre the recommendations for the emergency management of acute ischemic stroke patients on novel oral anticoagulants sufficient?Stroke201445ATMP57
   Google Scholar
• van RynJStangierJHaertterSDabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activityThromb Haemost201210361116112720352166
   PubMed Web of Science ®Google Scholar
• BlannADNon-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratoryBr J Biomed Sci201471415816725562993
   PubMed Web of Science ®Google Scholar
• SamamaMMContantKSpiroTEEvaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controlsThromb Haemost201210737938722187012
   PubMed Web of Science ®Google Scholar
• StangierJFeuringMUsing the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranBlood Coagul Fibrinolysis20122313814322227958
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim’s Investigational Antidote for Pradaxa^® (dabigatran etexilate mesylate) receives FDA breakthrough therapy designation [press release]Ridgefield, CTBoehringer Ingelheim2014626 Available from: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/06-26-14-boehringer-ingelheim-investigational-antidote-pradaxa-dabigatran-etexilate-me-sylate-fda-breakthrough-therapy-designation.htmlAccessed July 26, 2014
   Google Scholar
• LuGDeGuzmanFRHollenbachSJA specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNat Med201319444645123455714
   PubMed Web of Science ®Google Scholar